Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Sep;17(9):1187-93.
doi: 10.1007/s00520-008-0572-4. Epub 2009 Feb 10.

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron

Laurel M Adams  1 , Brendan Johnson, Ke Zhang, Lin Yue, Lyndon C Kirby, Peter Lebowitz, Randall Stoltz
Affiliations
Clinical Trial

Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron

Laurel M Adams et al. Support Care Cancer. 2009 Sep.

Abstract

Objective: The objective of this study was to characterize the impact of casopitant, a novel neurokinin-1 receptor antagonist under investigation for the prevention of postoperative and chemotherapy-induced nausea and vomiting, on the pharmacokinetics of the commonly prescribed 5-hydroxytryptamine receptor 3 receptor antagonists, dolasetron or granisetron.

Materials and methods: In a phase I, open-label, two-part, two-period, single-sequence study, two cohorts of healthy subjects received either oral dolasetron (100 mg once daily for 3 days) or oral granisetron (2 mg once daily for 3 days) alone (period 1) and combined with oral casopitant, 150 mg day 1, 50 mg days 2 and 3 (period 2). Pharmacokinetics of hydrodolasetron and granisetron were assessed on days 1 and 3 of each period. Log-transformed area under the curve (AUC) and Cmax were statistically analyzed by performing an analysis of variance. Eighteen subjects were enrolled in the dolasetron cohort; nine subjects were CYP2D6 extensive metabolizers (EMs) and nine subjects were CYP2D6 poor metabolizers. Nineteen subjects were enrolled in the granisetron cohort.

Results: The largest changes in hydrodolasetron exposure after coadministration with casopitant were seen in CYP2D6 EMs, with a 24% increase in hydrodolasetron AUC on day 1 and 30% increase in Cmax on days 1 and 3. All other changes in hydrodolasetron exposure were <20%, and granisetron exposure was not altered to any relevant extent (<11%).

Conclusion: None of the changes observed are considered clinically meaningful, and coadministration of casopitant with dolasetron or granisetron was well tolerated.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Day 1 and day 3 hydrodolasetron AUC(0-τ) and Cmax when a 3-day regimen of 100 mg oral dolasetron is given alone and in combination with a 3-day oral regimen of casopitant in CYP2D6 EMs (circles) and CYP2D6 PMs (triangles)
Fig. 2
Fig. 2
Day 1 and day 3 granisetron AUC(0-τ) and Cmax when a 3-day regimen of 2 mg oral granisetron is given alone and in combination with a 3-day oral regimen of casopitant
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1097/00000542-199909000-00022', 'is_inner': False, 'url': 'https://doi.org/10.1097/00000542-199909000-00022'}, {'type': 'PubMed', 'value': '10485781', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10485781/'}]}
    2. Apfel CC, Laara E, Koivuranta M et al (1999) A simplified risk score for predicting postoperative nausea and vomiting. Anesthesiology 91:693–700. doi:10.1097/00000542-199909000-00022 - PubMed
    1. Aventis (2006) Anzemet prescribing information. June
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/ddr.430340306', 'is_inner': False, 'url': 'https://doi.org/10.1002/ddr.430340306'}]}
    2. Bigaud M, Elands J, Kastner PR et al (1995) Pharmacology of the human metabolites of dolasetron, an antiemetic 5-HT3 receptor antagonist. Drug Dev Res 34:289–296. doi:10.1002/ddr.430340306
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PMC', 'value': 'PMC1364919', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC1364919/'}, {'type': 'PubMed', 'value': '7888294', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/7888294/'}]}
    2. Bloomer JC, Baldwin SJ, Smith GJ et al (1994) Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of granisetron. Br J Clin Pharmacol 38:557–566 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1517/14622416.3.2.229', 'is_inner': False, 'url': 'https://doi.org/10.1517/14622416.3.2.229'}, {'type': 'PubMed', 'value': '11972444', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11972444/'}]}
    2. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans, and their descendants. Pharmacogenomics 3:229–243. doi:10.1517/14622416.3.2.229 - PubMed

Publication types

MeSH terms

LinkOut - more resources